Skip to main content

Closed

IPHA: Innate Pharma S.A. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Operating margin-2058.0%

ROIC-155.5%

Financially safe

Stretched

Debt / equity-1.04×

Interest coverage-18.4×

Current ratio1.27×

Innate Pharma S.A.

IPHANASDAQ Global Select·USD·Closed

Innate Pharma S.A.

IPHANASDAQ·USD·Closed

$1.75

+0.29%

$1.75

+$0.00 (0.29%)

52W Range

40thpctl

Volume

0.14×avg

Mkt Cap

164.33MUSD

P/E

-2.8TTM

Div Yield

–ann

52W Range

40thpctl

Volume

0.14×avg

Market Cap

164.33MUSD

P/E Ratio

-2.8TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings